Neprilysin Inhibitor [EPC]

Known as: Neprilysin Inhibitor 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2016
01219982016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Heart failure still has a significant disease burden with poor outcomes worldwide despite advances in therapy. The standard… (More)
Is this relevant?
Review
2017
Review
2017
Mortality from heart failure remains high despite advances in medical therapy over the last three decades. Angiotensin receptor… (More)
  • figure 1
Is this relevant?
2017
2017
BACKGROUND Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with… (More)
Is this relevant?
Review
2017
Review
2017
The main stay pharmacotherapy for heart failure (HF) is targeted towards rennin-angiotensin-aldosterone (RAAS) and neprilysin… (More)
  • table 1
  • figure 1
Is this relevant?
Review
2016
Review
2016
WHAT IS KNOWN AND OBJECTIVE Heart failure remains a leading cause of morbidity and mortality worldwide. Advanced therapies have… (More)
Is this relevant?
Review
2016
Review
2016
Heart failure (HF) impacts an estimated 5.7 million Americans, and its prevalence is projected to increase to more than 8 million… (More)
Is this relevant?
2015
2015
Heart failure affects over five million Americans each year and contributes to morbidity, mortality, and high health care costs… (More)
  • table 1
  • table 2
Is this relevant?
Review
2015
Review
2015
Die chronische Herzinsuffizienz ist eine der häufigsten chronischen Erkrankungen weltweit, wobei Prävalenz und Inzidenz weiter… (More)
Is this relevant?
2014
2014
AIMS The first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Angiotensin-converting enzyme (ACE) inhibition alone or in combination with the angiotensin type-I receptor (AT1) antagonist… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?